Clin2
NCT04821778Possibly a fitRecruiting

Testing chemoradiotherapy for esophageal and stomach junction cancer

Esophagus CancerEsophagogastric Junction CancerChemoradiationTargeted TherapyImmunotherapyChemotherapy Effect

Treatments studied

Part of Cancer, Digestive system clinical trials.

This Phase 3 study tests a cancer treatment plan that combines chemotherapy and radiation for people with esophageal or esophagus-stomach junction cancer. It aims to see whether this approach works better than standard care for cancers at stages I to IVA.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
2,000 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are at least 18 years old
  • You have confirmed esophageal or esophagus-stomach junction cancer (either squamous cell or adenocarcinoma)
  • Your cancer is staged I to IVA (AJCC 8th edition)
  • Your general health score (ECOG) is 0 or 1, meaning you can do daily activities with little help
  • Your blood counts and organ blood tests are within required limits (like hemoglobin, white cells, platelets, and liver/kidney tests)
  • Your cancer does not already have spread to distant organs (like liver, lung, bone, or brain)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04821843Recruiting· Phase 3
Study before-surgery treatments for esophageal cancer

This Phase 3 trial compares different “treatments before surgery” for people with esophageal (or esophagus-to-stomach) cancer. It aims to see which approach works better to control the cancer and improve outcomes after surgery.

Beijing
NCT02988921Recruiting
MRI and CT planning for esophagus or stomach-junction cancer treatment

This study checks whether MRI and CT scans can better measure how esophageal or stomach-junction tumors respond during chemoradiotherapy and help doctors map the exact treatment area. It may help improve targeting while you receive standard treatment.

Beijing
NCT04989985Recruiting· Phase 2
SOX chemotherapy plus immunotherapy for junction stomach-esophagus cancer

This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.

Guangzhou, Guangdong
NCT06676449Recruiting· Phase 3
A study on radiation-sparing treatment for advanced esophageal cancer

This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.

Shanghai, Shanghai Municipality
NCT04278287Recruiting· Phase 1/Phase 2
Chemoradiation study for unresectable esophageal cancer

This Phase 1/2 trial tests a treatment plan using chemotherapy plus radiation for esophageal squamous cell cancer that cannot be removed with surgery. It may help shrink or control the cancer and guide safer dosing, but it’s only for people with specific tumor stage, health status, and blood test results.

Anyang, Henan
NCT04656041Recruiting· Phase 2
Test chemo with radiation for gastroesophageal cancer

This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.

Boston, Massachusetts

Hear when a new Esophagus Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.